Almost 70 product-specific guidances have been published by the US Food and Drug Administration at the start of June, with the 69 guidances published comprising 26 new PSGs and 43 revised documents.
Among the new PSGs are documents covering subcutaneous extended-release buprenorphine, estradiol extended-release vaginal inserts and fluorometholone ophthalmic suspension. They...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?